在结肠直肠癌的侵袭前线,协调的细胞社区编排抗瘤免疫力
Christian M Schürch1, Salil S Bhate2, Graham L Barlow1
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Cell
|August 9, 2020
概括
研究人员使用先进的成像绘制了结直肠癌 (CRC) 的瘤微环境. 特定的免疫细胞邻居与患者的生存相关, 为癌症免疫疗法提供了新的见解.
科学领域:
- 免疫学
- 癌症学
- 计算生物学
背景情况:
- 抗瘤免疫依赖于瘤微环境 (iTME) 内的复杂相互作用.
- 了解免疫细胞的空间组织对于推进癌症免疫疗法至关重要.
研究的目的:
- 开发和应用一种新的多重成像技术,用于详细分析结直肠癌 (CRC) iTME.
- 识别不同的细胞邻居 (CNs) 和它们与高级CRC患者的结果的关联.
主要方法:
- 通过索引重新设计的共检测 (CODEX) 用于嵌入素的组织微阵列.
- 在35名晚期CRC患者的140个组织区域同时分析56个蛋白质标记物.
- 计算分析以识别和描述9个保存的细胞社区 (CN).
主要成果:
- 在CRC iTME中确定了九个不同的,保存的细胞社区 (CN).
- 在高危患者小组中,粒细胞中PD-1+CD4+T细胞的丰富与改善的存活率相关.
- 瘤与免疫CN的合,CN的碎片化和CN之间的通信中断与较差的结果有关.
结论:
- 这项研究为了解CRC的抗瘤免疫提供了一个空间框架.
- 这些发现突显了细胞邻居组织和沟通在有效瘤控制中的重要性.
- 开发的CODEX方法为剖析癌症复杂的生物过程提供了强大的工具.
相关概念视频
The Tumor Microenvironment
7.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
Adaptive Mechanisms in Cancer Cells
6.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
Tumor Immunotherapy
1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Cancer Stem Cells and Tumor Maintenance
5.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K
Metastasis
6.2K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.2K
Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K


